论文部分内容阅读
目的探讨HAD方案治疗难治复发性急性髓系白血病的疗效及临床分析。方法 2009～2012年期间,我院诊治的42例难治复发性急性髓系白血病患者,随机将其分为对照组(FLAG方案治疗)和观察组(HAD方案治疗),每组各21例,对两组的临床疗效、不良反应,进行观察和比较。结果与对照组相比,观察组的缓解率明显升高不良反应发生率显著降低,P<0.05,差异有统计学意义。结论对于难治复发性急性髓系白血病患者,HAD方案治疗的疗效显著,不良反应少,值得临床推广。
Objective To investigate the efficacy and clinical analysis of HAD regimen in the treatment of refractory recurrent acute myeloid leukemia. Methods From 2009 to 2012, 42 patients with refractory recurrent acute myeloid leukemia treated in our hospital were randomly divided into control group (FLAG regimen) and observation group (HAD regimen treatment), 21 cases in each group, The two groups of clinical efficacy, adverse reactions, were observed and compared. Results Compared with the control group, the remission rate was significantly increased in the observation group and the incidence of adverse reactions was significantly decreased, P <0.05, the difference was statistically significant. Conclusion For the patients with refractory recurrent acute myeloid leukemia, the curative effect of HAD regimen is significant and the adverse reactions are few, which is worthy of clinical promotion.